Anti-HER2 immunoliposomes were reported to selectively bind to and internalize in HER2-overexpressing cancer cells in vitro, and doxorubicin-loaded anti-HER2 immunoliposomes exhibited marked therapeutic effects in HER2-overexpressing xenograft models [378]. The gene discussed is ERBB2; the disease is cancer.